For the present SMM patient with a tendency to progress, after induction therapy to reduce the tumor load, we accomplished lymphocytapheresis and succeeded in preparing the CD19- and BCMA-targeted chimeric antigen receptor T cells. The gene discussed is CD19; the disease is neoplasm.